SynthesisCanadian respiratory journal2025
Efficacy and Safety of Anticoagulants in Patients With Idiopathic Pulmonary Fibrosis: A Meta-Analysis.
Synthesis in Canadian respiratory journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and Safety of Anticoagulants in Patients With Idiopathic Pulmonary Fibrosis: A Meta-Analysis.Canadian respiratory journal · 2025Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: There is a known association between coagulation abnormalities and idiopathic pulmonary fibrosis (IPF), but it remains unclear whether anticoagulant treatment can extend the lifespan of IPF patients. This systematic review and meta-analysis aim to evaluate the efficacy and safety of anticoagulants in patients with IPF. Methods: A comprehensive search was conducted in PubMed, Embase, Cochrane, and Web of Science from their inception until June 30, 2024, with an English language restriction. We selected clinical studies that met the inclusion criteria after reviewing titles, abstracts, and full texts. Results: Three randomized controlled trials and five prospective studies, including 2185 patients, were analyzed. Compared to standard treatment, anticoagulants did not significantly affect overall mortality in IPF patients. However, excluding studies with warfarin monotherapy, other anticoagulants extended patient survival (OR = 0.56, 95% CI [0.33, 0.95], Conclusion: The study suggests that anticoagulants may extend the lifespan of IPF patients and improve lung function. However, they also increase the risk of adverse events such as bleeding. However, there is an increased risk of adverse events, such as bleeding. This may be due to the distinct mechanisms of action, risk profiles, and clinical outcomes of each drug, although the exact causes remain unclear. Further meta-analyses based on individual patient data are needed to confirm these findings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.